11/18
05:33 pm
sonn
Peripheral Nerve Injuries Market to Show Remarkable Growth at a CAGR of 6.19% by 2034 | DelveInsight [Yahoo! Finance]
Medium
Report
Peripheral Nerve Injuries Market to Show Remarkable Growth at a CAGR of 6.19% by 2034 | DelveInsight [Yahoo! Finance]
11/12
09:15 am
sonn
Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment
Medium
Report
Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment
11/6
01:20 pm
sonn
Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules
High
Report
Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules
11/6
08:30 am
sonn
Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates
High
Report
Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates
10/17
11:19 am
sonn
Sonnet BioTherapeutics regains compliance with Nasdaq [Seeking Alpha]
Low
Report
Sonnet BioTherapeutics regains compliance with Nasdaq [Seeking Alpha]
10/17
08:47 am
sonn
Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq [Yahoo! Finance]
High
Report
Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq [Yahoo! Finance]
10/17
08:45 am
sonn
Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq
High
Report
Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq
10/9
08:45 am
sonn
Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India
Neutral
Report
Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India
10/4
08:30 am
sonn
Sonnet BioTherapeutics to Receive Non-Dilutive Funding Through New Jersey Tax Certificate Transfer and Australia R&D Tax Incentive Programs
Low
Report
Sonnet BioTherapeutics to Receive Non-Dilutive Funding Through New Jersey Tax Certificate Transfer and Australia R&D Tax Incentive Programs
9/25
08:30 am
sonn
Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split
High
Report
Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split
9/18
08:30 am
sonn
Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors
Neutral
Report
Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors
9/4
09:15 am
sonn
Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell Series
High
Report
Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell Series
8/23
12:17 pm
sonn
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $30.00 price target on the stock.
Low
Report
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $30.00 price target on the stock.